SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus Bioscience Holdings Inc. (AMBS)

Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator joboggi, zoomboom, JJAAMMAANN, Rosym
Search This Board:
Last Post: 8/4/2015 1:33:35 PM - Followers: 723 - Board type: Free - Posts Today: 37


(AMBS) Amarantus BioScience Holdings, Inc. 

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
For further information, please visit, or connect with the company in FacebookTwitter, LinkedIn & Google+



Amarantus Announces Adjournment of Annual Meeting  -  The annual meeting has been adjourned to August 7, 2015 at 10:00 a.m. EDT at Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor, New York, New York 10006
Aug. 3, 2015
Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds - 
"This CRADA represents an important partnership for Amarantus as we work with the USAISR and Rutgers to advance the clinical program for ESS," said Gerald E. Commissiong, President & CEO of Amarantus.
AUGUST 03, 2015

Amarantus Diagnostics logo   Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
JULY 29, 2015
Amarantus BioScience Initiation of coverage Building up therapeutics assets
July 27, 2015
Amarantus Diagnostics Establishes Strategic Advisory Committee - Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies
July 27, 2015 
SeeThruEquity Initiates Coverage on Amarantus BioScience Holdings, Inc. with a Price Target of $45.34
JULY 24, 2015
Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R)
July 22, 2015
Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
JULY 20, 2015
Amarantus Closes Cutanogen Acquisition
By Jason Napodano, CFA  -  Wednesday, July 15, 2015

Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns  -  Amarantus Now Has Full Ownership of Cutanogen Corporation, Which Has Exclusive Worldwide License to Orphan Drug Product Candidate Engineered Skin Substitute (ESS)  -  July 15, 2015
Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS - Company Progressing Toward a National Stock Exchange Listing. -  July 13, 2015
Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease  -  Patent Provides IP Protection for Lead Product Candidate Eltoprazine for the Treatment of Parkinson's Disease    -   June 30, 2015
Amarantus Sets Sights On NASDAQ
Jason Napodano, CFA   -   May 29, 2015  

Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia - Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch -  Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015 
May 21, 2015
Amarantus Reports First Quarter 2015 Financial Results and Business Overview  - Eltoprazine Phase 2b clinical program on track to commence in 2Q 2015 -     
May 20, 2015   
Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease - Demonstrated MANF Can be Precisely Delivered to Parkinson's-Associated Brain Areas.
May 15, 2015
MANF Begins its March Towards the Clinic
May 14th, 2015

More News



 Gerald E. Commissiong on LymPro 
Published on Jul 24, 2015

Predicting Alzheimer's before it starts
 Published on Apr. 8, 2015

Developing an Accurate Test for Multiple Sclerosis
Mar. 5, 2014

SNNLive - Amarantus BioScience Holdings, Inc
Dec. 12, 2014


Amarantus BioScience
Oct. 19, 2014




Company Information

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111


c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva

Phone: (415) 688-4484
Fax: (408) 852-4427

Gerald's email address

IR Calendar 



Jenene Thomas Communications
Jenene Thomas
T: 908-938-1475



VStock Transfer, LLC
Allison Niccols
77 Spruce Street
Suite 201
Cedarhurst, N 11516
T: 212-828-8436
F: 646-536-3179


Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.

  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

                           2 Conferences

EDT at Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor, New York, New York 10006 -  August 7, 2015 at 10:00 a.m.
The beneficial stockholders may vote by internet at, or by telephone at 800-454-8683 

First MANF & CDNF Proteins Symposium - Two-Day International Symposium, San Francisco, CA  -  September 14 -15, 2015 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AMBS News: Additional Proxy Soliciting Materials (definitive) (defa14a) 06:35 AM
AMBS News: Current Report Filing (8-k) 08/03/2015 05:30:48 PM
AMBS News: Amarantus Announces Adjournment of Annual Meeting 08/03/2015 05:30:00 PM
AMBS News: Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ES... 08/03/2015 06:00:00 AM
AMBS News: Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Mult... 07/29/2015 07:35:00 AM
News News Alert: Additional Proxy Soliciting Materials (definitive) (defa14a) 08/04/2015 06:35:19 AM
#116737  Sticky Note Jason Napodano, CFA ?@JNapodano 12h12 hours ago Rosym 08/04/15 08:53:08 AM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#116762   Right...but if you say basher the post gets deleted. brharris 08/04/15 01:53:55 PM
#116761   where's the FDA rejection notice JPetroInc 08/04/15 01:51:21 PM
#116760   there are no "shorts" der_deutschetrader 08/04/15 01:33:35 PM
#116759   "Watch JP just for the flip" JPetroInc 08/04/15 01:04:13 PM
#116758   It was discussed on a call, I believe brharris 08/04/15 12:13:57 PM
#116757   Poor ValuEngine is always about a day late. Trashboy 08/04/15 11:23:06 AM
#116756   Amaranuts is sorta like the clippers in the SidVicious 08/04/15 11:21:57 AM
#116755   Zoomboom - do you think the uplist can GoClippers 08/04/15 11:19:05 AM
#116754   DJIA: 17,588.84 -9.36 (-0.05%) / NASDAQ: 5,106.757 Denny24 08/04/15 11:17:20 AM
#116753   When did the company report that? Is there SidVicious 08/04/15 11:14:15 AM
#116752   Gerald is very accessible try his email and zoomboom 08/04/15 11:07:51 AM
#116751   They has plenty of time to talk yesterday brharris 08/04/15 10:49:16 AM
#116750   AMBS will not trade on NASDAQ now or Groot 08/04/15 10:43:46 AM
#116749   They have more than $5 million per the brharris 08/04/15 10:16:16 AM
#116748   Requested more information...which is often the case!!! Next brharris 08/04/15 10:06:00 AM
#116747  Restored as Gomer Pyle would say der_deutschetrader 08/04/15 09:51:23 AM
#116746   uplist to NASDAQ der_deutschetrader 08/04/15 09:49:27 AM
#116745   Great post by Finalstretch63on the other board. He Slmiley 08/04/15 09:32:05 AM
#116744   Warning! 150-1 Reverse Split in play. Shares will Sgt. Pepper 08/04/15 09:16:01 AM
#116743   Beware! PRE RS was trading at .04 Sgt. Pepper 08/04/15 09:15:44 AM
#116742   They didn't approve it did they? So if SidVicious 08/04/15 09:11:33 AM
#116741   It was very nice to meet some of brharris 08/04/15 09:10:12 AM
#116740   Technically there was no meeting yesterday. Shadowfaxin 08/04/15 09:05:15 AM
#116739   Not going to happen! NASDAQ will happen and brharris 08/04/15 09:03:21 AM
#116738   I hope they don't reject them like the SidVicious 08/04/15 08:59:51 AM
#116737   Jason Napodano, CFA ?@JNapodano 12h12 hours ago Rosym 08/04/15 08:53:08 AM
#116736   I despise this poster but this has got Loco Motion 08/04/15 08:41:58 AM
#116735   DO not get confused guys. Do not get christjamin 08/04/15 08:37:14 AM
#116734   Buddy, you are one of the smartest guy christjamin 08/04/15 08:33:05 AM
#116733   SAC is on it, and comparables were made JPetroInc 08/04/15 08:08:13 AM
#116732   Was there any discussion about the diagnostic spin off? SidVicious 08/04/15 07:24:33 AM
#116731   Can you define what you believe to be SidVicious 08/04/15 07:11:30 AM
#116730   Officially, the NASDAQ listing application has been filed Salexander1 08/04/15 06:55:59 AM
#116729 Rosym 08/04/15 06:44:09 AM
#116728   and this is a phase II study, it joboggi 08/04/15 05:59:12 AM
#116727   Someone asserted that dilutive financing was good. Well, joboggi 08/04/15 05:22:44 AM
#116726   Re trashboy 116720: It was through AMBS website. Shadowfaxin 08/04/15 12:10:29 AM
#116723   PROVE THAT STATEMENT PLEASE 27times 08/03/15 11:07:05 PM
#116722   No worries. They will get their shares back. GS1 08/03/15 11:00:07 PM
#116721   Either you are a savvy investor or you christjamin 08/03/15 10:36:08 PM
#116720   Shadow, is that through your broker? Trashboy 08/03/15 10:15:15 PM
#116719   I believe that Financier Dominion sold all of Rosym 08/03/15 10:10:01 PM
#116718   Proxy vote? Shadowfaxin 08/03/15 10:01:08 PM
#116717   If the company successfully makes it to NASDAQ; Salexander1 08/03/15 09:38:00 PM
#116716   LOL! Trashboy 08/03/15 09:22:16 PM
#116715   Setting up the habitual AMBS flippers to flip zoomboom 08/03/15 09:03:43 PM
#116714   MStrike - nice meeting you as well JPetroInc 08/03/15 08:57:44 PM
#116713   JP, thank you for your posts, you pointed mstrike 08/03/15 08:45:00 PM
#116712   Just received my proxy half an hour ago... mazennnn 08/03/15 07:56:00 PM
#116710   Thanks again. One more. SidVicious 08/03/15 07:36:29 PM